A shorter symptom onset to remdesivir treatment (SORT) interval is associated with a lower mortality in moderate-to-severe COVID-19: A real-world analysis
Objectives: Remdesivir is the current recommended anti-viral treatment in moderate-to-severe COVID-19. However, data on impact of timing of therapy, efficacy, and safety are limited. We evaluated the impact of timing of remdesivir initiation (symptom onset to remdesivir treatment [SORT] interval) on...
Main Authors: | Ravindra M. Mehta, Sameer Bansal, Suhitha Bysani, Hariprasad Kalpakam |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-05-01
|
Series: | International Journal of Infectious Diseases |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1201971221001788 |
Similar Items
-
Remdesivir Treatment for COVID 19 in Pregnant Patients with Moderate to Severe Symptoms: Serial Case Report
by: Yudianto Budi Saroyo, et al.
Published: (2021-05-01) -
Remdesivir – Current evidence & perspective in management of COVID-19 infection
by: Jyoti Bajpai, et al.
Published: (2021-01-01) -
Clinical outcomes of using remdesivir in patients with moderate to severe COVID-19: A prospective randomised study
by: Lakshmi Mahajan, et al.
Published: (2021-01-01) -
Remdesivir for coronavirus 2019 (COVID-19): More promising but still unproven
by: Richard D. Shih, et al.
Published: (2020-12-01) -
Remdesivir use in the coronavirus disease 2019 pandemic: A mini-review
by: Chih-Jen Yang, et al.
Published: (2021-02-01)